Microvascular obstruction in acute coronary syndromes: Onward to a new therapeutic target

Catheterization and Cardiovascular Interventions

Volumn 66, Issue 2, 2005, Pages 170-172

  Schwartz, Robert S ^a  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; STREPTOKINASE; TENECTEPLASE; THROMBIN INHIBITOR; TIROFIBAN; UROKINASE;

AGED; BLOOD VESSEL OCCLUSION; CASE REPORT; ENZYME BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; MALE; MICROCIRCULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY STENOSIS; CREATINE KINASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; STENTS; TREATMENT OUTCOME;

EID: 26644450733     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20510     Document Type: Review

References (13)

1. Camilleri JP, Joseph D, Fabiani JN, Deloche A, Schlumberger M, Relland J, Carpentier A. Microcirculatory changes following early reperfusion in experimental myocardial infarction. Virch Arch A Pathol Anat Histol 1976;369:315-333.
2. Wilson RF, Laxson DD, Lesser JR, White CW. Intense microvascular constriction after angioplasty of acute thrombotic coronary arterial lesions. Lancet 1989;1:807-811.
3. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeigh ER, Furuta T, Becker LC, Melin JA. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998;98:1006-1014.
4. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, Blumenthal RS, Lima JA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-772.
5. Gerber BL, Rochitte CE, Melin JA, McVeigh ER. Bluemke DA, Wu KC, Becker LC, Lima JA. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000;101:2734-2741.
6. Michaels AD, Gibson CM. Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol 2000;85:50B-60B.
7. de Lemos JA, Warner JJ. New tools for assessing microvascular obstruction in patients with ST elevation myocardial infarction. Heart 2004;90:119-120.
8. Choi CJ. Haji-Momenian S. Dimaria JM. Epstein FH, Bove CM. Rogers WJ, Kramer CM. Infarct involution and improved function during healing of acute myocardial infarction: the role of microvascular obstruction. J Cardiovasc Magn Reson 2004;6:917-925.
9. Sandstede JJ. Assessment of myocardial viability by MR imaging. Eur Radiol 2003;13:52-61.
10. Lesser JR, Johnson K, Lindberg JL, Reed J, Tadavarthy SM, Virmani R, Schwartz RS. Images in cardiovascular medicine: myocardial rupture, microvascular obstruction, and infarct expansion-elucidation by cardiac magnetic resonance. Circulation 2003;108:116-117.
11. Lincoff AM, Califf RM, Van de Werf F, Willerson JT, White HD, Armstrong PW, Guetta V, Gibler WB, Hochman JS, Bode C, Vahanian A, Steg PG, Ardissino D, Savonitto S, Bar F, Sadowski Z, Betriu A, Booth JE, Wolski K, Waller M, Topol EJ. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002;288:2130-2135.
12. Manoharan G, Adgey AA. Considerations in combination therapy: fibrinolytics plus glycoprotein IIb/IIIa receptor inhibitors in acute myocardial infarction. Clin Cardiol 2004;27: 381-386.
13. Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials. J Thromb Thrombolysis 2002;14:197-203.